



CERTIFICATE OF ANALYSIS

Manufacturing Country: ITALY
Importing country: Ukraine

Reg. certificate in Ukraine: UA/15678/01/01
Date of registration: 22.04.2022
Date of Expiry: 22.04.2027

Product name	Ismigen sublingual tablets in 50 mg	Lot No.	D808
Active ingredient and amount per unit dose	Bacterial lysate 50 mg, 7 mg of which corresponds to: <i>Staphylococcus aureus</i> 6x10 ⁹ CFU, <i>Streptococcus pyogenes</i> 6x10 ⁹ CFU, <i>Streptococcus viridans</i> 6x10 ⁹ CFU, <i>Klebsiella pneumoniae</i> 6x10 ⁹ CFU, <i>Klebsiella ozaenae</i> 6x10 ⁹ CFU, <i>Haemophilus influenzae B</i> 6x10 ⁹ CFU, <i>Neisseria catarrhalis</i> 6x10 ⁹ CFU, <i>Streptococcus pneumoniae</i> 6x10 ⁹ CFU (the last bacteria contains 1x10 ⁹ CFU of the following types: TY1, TY2, TY3, TY5, TY8, TY47), and 43 mg of glycine for lyophilization process	Mfg. Date	18/04/2024
Dosage form	sublingual tablets in 50 mg	Exp. Date	31/03/2027
Package size and type	Nº30 tablets in blisters	Sampling Date	29/04/2024
Batch No.	D808	Analysis Date	09/05/2024
Batch Size	11613	Release Date	09/05/2024
QC Appr. No.	2402644	Pharmaceutical Ref.	See below
Manufacturing authorisation	aM77/2023 dated 30/05/2023	G.M.P. Certificate	GMP IT/91/11/2023 dated 30/05/2023
Name Mfg.	Bruschetti S.R.L.	Address	Via Isonzo 6, 16147 Genova, Italy

Sr. No.	TEST	SPECIFICATION	RESULTS
1	Description, organoleptically	Whitish tablets with a scored line on one side, brownish spots, with a light characteristic odour	Complies
2	Authenticity In-house method, EIA (ELISA)	Has to contain a mixture of bacterial lysates: <i>Staphylococcus aureus</i> <i>Streptococcus pyogenes</i> <i>Streptococcus viridans</i> <i>Klebsiella pneumoniae</i> <i>Klebsiella ozaenae</i> <i>Haemophilus influenza B</i> <i>Neisseria catarrhalis</i> <i>Streptococcus pneumoniae</i>	Complies
3	Uniformity of weight (EP, p 2.9.5)	Complies with EP	Complies
4	Average weight (EP, p 2.9.5)	238,0 – 262,0 mg	250,3
5	Disintegration (EP, p 2.9.1, Test A)	NMT 15 min	4
6	Hardness (EP, p 2.9.8)	NLT 3 kg	18,0
7	Water content (p 2.5.12, Method A (method K. Fisher))	NMT 8%	3,671
8	Immunostimulant activity (In-house)		
	- Activity	More than 30%	CD83: 270%; CD86: 3875%
	- Comparison with positive control	CD83 vs PGN: 50-200% CD86 vs PGN: 50-200%	76% 86%



CERTIFICATE OF ANALYSIS

9	Microbiological purity (EP, p 2.6.12, p 2.6.13, p 5.1.4)	Not over 10 ³ aerobic bacteria (TAMC), Not over 10 ² fungi and molds (FYM), Absent <i>Escherichia coli</i> /1 g.	10 <10 Absent
---	---	--	---------------------

Comments: The batch complies to the prescribed standards of quality as per In-House specification

Certification statement: "I hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including packaging/labelling and quality control at the above mentioned site(s) in full compliance with the GMP requirements of the local Regulatory Authority and with the specifications in the Marketing Authorisation of the importing country or product specification file for Investigational Medicinal Products. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP."

Analysed by		Checked by		Approved by	
Name	Marco Modugno	Name	Isabella De Marco	Name	Laura Agrimi
Designation	Analyst	Designation	QC Manager	Designation	QP, QA Manager
Sign/Date	09/05/2024	Sign/Date	09/05/2024	Sign/Date	09/05/2024